NCT05659914 - Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

June 1, 2026

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

olaparib+durvalumab

olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w

Trial Locations (3)

Complejo Hospitalario Universitario La Coruña, A Coruña

Hospital Universitari Vall d´Hebron, Barcelona

Hospital Universitario Marqués de Valdecilla, Santander